From Hormone to Cultural Obsession
Testosterone has moved from endocrinology textbooks into everyday debate about masculinity, fitness and politics. Tech moguls’ newly built physiques, podcast hosts discussing hormone regimens, and high-profile officials openly touting testosterone replacement therapy (TRT) have helped propel the hormone into the spotlight. Prescriptions have soared, with one market analysis showing a jump from under 1 million testosterone prescriptions in 2000 to nearly 12 million by 2025. That figure likely understates use, as more men obtain testosterone through telehealth services that frame TRT as a lifestyle upgrade rather than a treatment for disease. Policy moves to broaden access are welcomed by clinicians who see genuinely untreated hypogonadism, yet they also warn that an online culture obsessed with being ever more ‘alpha’ is fuelling demand among younger, otherwise healthy men chasing performance, aesthetics and status.
How Men’s Health Companies Sell ‘Low T’
Direct-to-consumer men’s health companies now sit at the centre of the low testosterone marketing boom. Brands such as Voy, Hims and Numan target men scrolling social media with slick ads promising solutions to fatigue, weight gain, hair loss, erectile problems and vague malaise. Because advertising prescription testosterone directly is restricted in many places, they promote blood tests and online assessments instead. Once men enter these funnels, TRT is often presented as a convenient, one-stop answer to midlife frustrations. A typical path involves at-home blood kits, brief virtual consultations and rapid prescriptions, sometimes even when traditional clinicians have deemed testosterone levels within the normal range. Influencer partnerships amplify the message: testimonials about newfound energy, shredded physiques and renewed confidence circulate on TikTok and other platforms, blurring the line between medical intervention and aspirational self-improvement product.
The Making of a Testosterone ‘Pseudo-Disease’?
Behind the testosterone treatment hype lies a scientific reality that is far more nuanced than the marketing suggests. True testosterone deficiency, or hypogonadism, involves both measurably low hormone levels and characteristic symptoms such as absent morning erections, markedly low libido, infertility, weight gain, osteoporosis and depression. Yet men’s natural testosterone levels vary widely, and what counts as ‘low’ is contested. Some endocrinologists argue that commercial campaigns are pathologising normal variation and the ordinary struggles of ageing, effectively inventing a testosterone pseudo-disease to expand the customer base. They report clinics “clogged” with men anxious about borderline results flagged by online tests or Reddit threads. Critics worry that framing irritability, modest weight gain or flagging gym progress as signs of ‘low T’ medicalises everyday life while distracting from first-line fixes like better sleep, diet, exercise and mental health care.
When TRT Helps — And When It May Harm
Testosterone therapy can be transformative for men with clear-cut hypogonadism, and patient stories reflect this. Some describe long-standing low mood, lack of sexual function and profound fatigue lifting once their hormone deficiency is properly treated. For others, however, the path is less straightforward. Starting TRT suppresses the body’s own testosterone production, meaning some men become dependent on injections or gels for life, a trade-off they may not fully grasp amid glowing influencer narratives. The treatment also carries risks, including potential effects on fertility, blood thickening and cardiovascular health, which require monitoring. Clinicians emphasise that a diagnosis should be based on repeated morning blood tests, thorough symptom assessment and investigation of underlying causes like obesity or liver disease. In contrast, rapid-fire online approvals risk bypassing that careful work-up in favour of quick, market-driven solutions.
Bridging the Gap Between Evidence and Hype
The gulf between clinical evidence and low testosterone marketing continues to widen. On one side are companies and influencers promising that optimising ‘T’ will fix everything from mood and masculinity to career drive. On the other are endocrinologists calling for restraint, better public education and stricter prescribing criteria. Many experts support responsible TRT access but argue it should follow comprehensive evaluation and prioritise underlying lifestyle changes. They also worry that the current narrative reinforces narrow, hypermasculine ideals: in some online spaces, ‘low T’ has become an insult, equated with weakness or political softness. A more grounded approach would treat testosterone as one hormone among many, not a shortcut to a better life. That means separating genuine medical need from commercial testosterone treatment hype, resisting pseudo-disease framing, and centring evidence-based care over algorithm-fuelled promises.